Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04580394 · ClinicalTrials.gov registry record · Phase 2
Crossover Trial of AD109 in Obstructive Sleep Apnea
A Phase 2 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT04580394 is a Phase 2 study that has completed, run by Apnimed. The registered enrollment target is 60 participants.
The verdict
NCT04580394, a Phase 2 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- DRUG AD109
- DRUG R-oxybutynin
- DIAGNOSTIC_TEST Digit System Substitution Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04580394
The ClinicalTrials.gov registry entry for NCT04580394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04580394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04580394 about?
NCT04580394 is a clinical study titled "Crossover Trial of AD109 in Obstructive Sleep Apnea". This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.
What is the current status of trial NCT04580394?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-10-27. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT04580394?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), AD109 (DRUG), R-oxybutynin (DRUG), Digit System Substitution Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04580394?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.